| Title | Effects of paclitaxel and nuclear factor NF-κB inhibitor in thyroid cancer tumors in vivo |
| Publication Type | Journal Article |
| Year of Publication | 2014 |
| Authors | Pushkarev, VM, Kovzun, OI, Pushkarev, VV, Tronko, MD |
| Abbreviated Key Title | Dopov. Nac. akad. nauk Ukr. |
| DOI | 10.15407/dopovidi2014.05.164 |
| Issue | 5 |
| Section | Medicine |
| Pagination | 164-167 |
| Date Published | 5/2014 |
| Language | Ukrainian |
| Abstract | Nuclear factor kappa B (NF-κB) inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) enhances the therapeutic effect of paclitaxel on tumors formed by the xenotransplantation of anaplastic thyroid carcinoma FRO cells. In animals treated with paclitaxel and NF-κB inhibitor, a reduction in the tumor volume was observed, which is significantly different from the effects of each of the compounds in particular. Thus, the combined use of paclitaxel and NF-κB inhibitor is a promising strategy for further preclinical studies for developing the new chemotherapeutic approaches for the anaplastic thyroid cancer treatment. |
| Keywords | inhibitor, nuclear factor, paclitaxel, thyroid cancer tumors |
1. Jordan M. A., Wilson L. Nat. Rev. Canc., 2004, 4: 253–265. https://doi.org/10.1038/nrc1317
2. Pushkarev V. M., Starenki D. V., Saenko V. A. et al. Endocrinology, 2004, 145, No. 7: 3143–3152. https://doi.org/10.1210/en.2004-0127
3. Tronko M. D., Pushkarev V. V., Kovzun O. I., Pushkarev V. M. Endokrynologiia, 2013, 18, No. 2: 78-91 (in Ukrainian).
4. Orlowski R. Z., Baldwin A. S., jr. Trends Mol. Med., 2002, 8, No. 8: 385–389. https://doi.org/10.1016/S1471-4914(02)02375-4
5. Liptay S., Weber C. K., Ludwig L. et al. Int. J. Cancer., 2003, 105: 735–746. https://doi.org/10.1002/ijc.11081
6. Karin M. Cell Res., 2008, 18: 334–342. https://doi.org/10.1038/cr.2008.30
7. Wang H., Cho C. H. Curr. Cancer Drug Targets., 2010, 10, No. 6: 593–599. https://doi.org/10.2174/156800910791859425
8. Pacifico F., Mauro C., Barone C. et al. J. Biol. Chem., 2004, 279, No. 52: 54610–54619. https://doi.org/10.1074/jbc.M403492200
9. Pacifico F., Leonardi A. Mol. Cell. Endocrinol., 2010, 321, No. 1: 29–35. https://doi.org/10.1016/j.mce.2009.10.010
10. Kovzun O. I., Pushkarev V. V. Endokrynologiia, 2005, 10, No. 1: 130–133 (in Ukrainian).
11. Chen W., Li Z., Bai L., Lin Y. Front. Biosci., 2011, 16: 1172–1185. https://doi.org/10.2741/3782
12. Luo J. L., Kamata H., Karin M. J. Clin. Invest., 2005, 115, No. 10: 2625–2632. https://doi.org/10.1172/JCI26322
